Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Caredx Inc (CDNA)

187 + Investors. Track Smart Money conviction in CDNA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -9
Streak
1Q ▼
Buyers last Q
51%

Smart Money Signals — CDNA

Based on 188 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their CDNA positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 87% of 3.0Y peak

87% of all-time peak
188 funds currently hold this stock — 87% of the 3.0-year high of 217 funds (reached 2025 Q1). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 13% fewer funds vs a year ago

fund count last 6Q
29 fewer hedge funds hold CDNA compared to a year ago (-13% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 51% buying

97 buying94 selling
Last quarter: 97 funds bought or added vs 94 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-18 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 24 → 36 → 42 → 24. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

64% of holders stayed for 2+ years

■ 64% conviction (2yr+) ■ 19% medium ■ 18% new
120 out of 188 hedge funds have held CDNA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~24 new funds/quarter

41 → 24 → 36 → 42 → 24 new funds/Q
New funds entering each quarter: 24 → 36 → 42 → 24. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Deep conviction — 69% of holders stayed 2+ years

■ 69% veterans ■ 10% 1-2yr ■ 22% new
Of 189 current holders: 130 (69%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 27% AUM from major funds

27% from top-100 AUM funds
43 of 188 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
2.8
out of 10
Low Exit Risk
Exit risk score 2.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CDNA

In 2026 Q1, 97 hedge funds were net buyers of CDNA (24 opened a new position, 73 added to an existing one), while 94 reduced or exited (61 trimmed, 33 sold completely) — a 51% buyer ratio, indicating a slight buying edge. 27% of total institutional value in CDNA is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -9 funds (more exits than new entries). Total institutional holders: 188.

Hedge Fund Ownership: CDNA

How many hedge funds hold CDNA — quarterly history vs. share price
Quarterly hedge fund ownership of CDNA vs. share price

Market Analysis: CDNA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CDNA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Caredx Inc (CDNA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CDNA has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
CDNA
+33.9%
XLV
+2.8%

CDNA outperformed XLV by +31.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
CDNA
+16.4%
XLV
+3.9%

Since the filing became public, CDNA outperformed XLV by +12.5% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

20 top-rated funds 1 high-conviction
Consensus
5.7
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: CDNA
187 + Investors

Track Smart Money conviction in CDNA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 187 197 -5.08%
13F Shares 52M 52M 0.21%
Total Value $902M $983M -8.21%
New Positions 23 42 -19
Increased Positions 71 61 +10
Closed Positions 33 29 +4
Reduced Positions 60 64 -4
Total Calls 1 2 -50.0%
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: CDNA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

187 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CDNA. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CDNA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Blue Water Life Science Advisors, LP 13.02% 935,000 $16.2M
2 Paragon Associates & Paragon Associates II Joint Venture 11.80% 500,000 $8.7M
3 Gagnon Securities LLC 7.06% 1,761,874 $30.6M
4 Gagnon Advisors, LLC 6.81% 532,892 $9.3M
5 Ophir Asset Management Pty Ltd 2.00% 988,051 $17.2M
6 Palo Alto Investors LP 1.41% 531,870 $9.2M
7 Braidwell LP 1.26% 2,173,146 $37.7M
8 Zweig-DiMenna Associates LLC 0.94% 390,255 $6.8M
9 Formula Growth Ltd 0.61% 78,478 $1.4M
10 Parkman Healthcare Partners LLC 0.52% 291,378 $5.1M
11 Deerfield Management Company, L.P. 0.45% 2,191,000 $38.0M
12 Amova Asset Management Americas, Inc. 0.36% 1,475,126 $25.6M
13 Meridiem Capital Partners LP 0.36% 316,950 $5.5M
14 Virtus Advisers, LLC 0.33% 40,564 $704K
15 Portolan Capital Management, LLC 0.31% 340,352 $5.9M
16 Globeflex Capital L P 0.31% 119,252 $2.1M
17 ARK Investment Management LLC 0.30% 2,227,556 $38.7M
18 nVerses Capital, LLC 0.27% 17,350 $301K
19 ArrowMark Colorado Holdings LLC 0.22% 486,668 $8.4M
20 Bamco Inc /Ny/ 0.17% 3,336,409 $57.9M
21 Palumbo Wealth Management LLC 0.15% 36,410 $632K
22 IQ EQ FUND MANAGEMENT (IRELAND) Ltd 0.13% 101,747 $1.8M
23 Uniplan Investment Counsel, Inc. 0.11% 62,773 $1.1M
24 Royce & Associates LP 0.09% 553,197 $9.6M
25 1492 Capital Management LLC 0.08% 12,534 $218K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Caredx Inc (CDNA)

What does the Smart Money Trend signal show for CDNA?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CDNA positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CDNA?

Slight buying edge — 51% buying: Last quarter: 97 funds bought or added vs 94 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CDNA holders?

Strong quality — 27% AUM from major funds: 43 of 188 holders rank in the top 100 by AUM, accounting for 27% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CDNA?

64% of holders stayed for 2+ years: 120 out of 188 hedge funds have held CDNA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Caredx Inc (CDNA) following the 2026 Q1 hedge fund 13F filings?

As of today, CDNA has moved +16.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +12.5%. Since the quarter end (March 31, 2026), CDNA has gained +33.9% vs +2.8% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →